Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Profit After Tax (2016 - 2025)

Historic Profit After Tax for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.

  • China Pharma Holdings' Profit After Tax rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3245.82%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
  • Latest data reveals that China Pharma Holdings reported Profit After Tax of -$651482.0 as of Q3 2025, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Profit After Tax ranged from a high of -$475976.0 in Q1 2023 and a low of -$1.4 million during Q2 2024
  • Over the past 5 years, China Pharma Holdings' median Profit After Tax value was -$826669.0 (recorded in 2021), while the average stood at -$903544.7.
  • In the last 5 years, China Pharma Holdings' Profit After Tax tumbled by 641855.51% in 2021 and then soared by 6326.01% in 2025.
  • Over the past 5 years, China Pharma Holdings' Profit After Tax (Quarter) stood at -$980719.0 in 2021, then fell by 28.9% to -$1.3 million in 2022, then grew by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then surged by 46.79% to -$651482.0 in 2025.
  • Its Profit After Tax was -$651482.0 in Q3 2025, compared to -$528367.0 in Q2 2025 and -$800000.0 in Q1 2025.